Thymulin Research

Thymulin is a thymic nonapeptide whose biological activity depends on a bound zinc ion, and that dependence defines the molecule. It is what separates thymulin from the zinc-free peptide of the same amino acid sequence, which its discoverers reported as inactive.

What thymulin is

The product record for Thymulin declares CAS 63958-90-7, molecular formula C33H54N12O15 and molecular weight 858.86 g/mol. PubChem CID 3085284 returns the same formula, gives the weight as 858.9, and titles the record nonathymulin, the international nonproprietary name ^[16].

Neither that formula nor the structure behind that CAS contains zinc, and a second CAS, 78922-62-0, maps to PubChem CID 71300623 with one stereocenter unspecified ^[16]. That record encodes no zinc either, so neither of those two CAS numbers describes the zinc complex.

That matters because of how the compound was named. Dardenne and colleagues showed in 1982 that the serum thymic factor loses activity in a rosette bioassay after non-specific metal chelation with Chelex-100 ^[1]. Activity returned when zinc salts were added, for the natural and synthetic peptide alike, and a one-to-one metal-to-peptide ratio was optimal ^[1]. Certain other metals restored activity too, to a lesser extent than zinc ^[1]. The zinc-free form was reported inactive, and the authors proposed the name thymulin for the zinc-bearing form ^[1]. That was in vitro and biochemical work.

The practical consequence is a naming gap, because no published study establishes the zinc content of a lyophilized powder sold as thymulin. FDA's drug directory carries four bulk ingredient listings whose active ingredient is nonathymulin, under three different generic names: Nonathymulin, Thymulin Acetate and Zinc Thymulin ^[17]. Those three names separate a zinc-free peptide, an acetate salt and a zinc complex within the supply chain's own labeling. A directory listing is a naming fact and not an approval ^[17].

Compounds thymulin is not

Thymulin is easily confused with other thymic preparations. Thymosin alpha-1 is a 28-residue peptide with its own trial record, and thymopentin is a pentapeptide fragment of thymopoietin. Thymosin fraction 5 and thymostimulin are thymus extracts rather than defined peptides. Thymalin is a bovine thymus extract with its own literature, and it appears as a synonym on PubChem CID 3085284, which is a naming collision rather than a shared identity ^[16].

The 2011 Cochrane review of thymic peptides in cancer patients pooled 26 human trials of thymostimulin, thymosin fraction 5, thymopentin and thymosin alpha-1 ^[15]. Thymulin is in none of those 26 trials, so the review's findings describe those four compounds and not thymulin ^[15].

Mechanism of action

Beyond the 1982 rosette bioassay, bench work has probed the zinc-bound molecule in two further ways, immunochemically and by NMR. Two monoclonal antibodies raised against thymulin, AS1 and AE1, recognized only the zinc-coupled form ^[2]. Antibodies screened instead on a zinc-deprived substrate recognized a zinc-independent epitope ^[2]. The immunochemical evidence is therefore not uniformly zinc-specific. The authors read the AS1 and AE1 result as a zinc-specific conformation ^[2]. That was in vitro immunochemical bench work. NMR analysis of the zinc-nonapeptide complexes identified specific serine and asparagine ligands, and only the one-to-one complex was antibody-recognized ^[3]. That was in vitro structural work.

Downstream signaling is less settled, and the newest proposal is inhibition of NF-kB ^[11]. One older paper reporting thymulin effects on NF-kB in rat hippocampus was retracted in 2010 ^[12]. That paper is one of six thymulin papers indexed under the same lead author ^[12]. The 2026 NF-kB proposal comes from a different group and rests on mouse and human cell work ^[11].

Human research

Human trials of thymulin exist, and they are few, small and old. Two randomized, double-blind, placebo-controlled trials in rheumatoid arthritis were reported together in 1987, comparing several dose levels ^[4]. At one of those levels, global assessment improved in 56 percent of patients against 17 percent on placebo, with four objective parameters also favoring treatment and minimal adverse effects ^[4]. The same abstract states the effect was not associated with clear changes in immunological parameters ^[4]. It also reports a significant correlation involving clinical response and T cell subset imbalance ^[4]. The published abstract does not report how many patients were enrolled ^[4]. Both trials came from the same Paris program and the same 1987 paper, so together they are one result rather than a result and an independent replication ^[4]. A 1984 communication from the same program and a 1987 open trial were published as letters, and PubMed indexes neither with an abstract ^[5][6].

The last controlled human trial of thymulin was a double-blind pilot study, and it ended negative ^[7]. Forty matched patients with evolutive multiple sclerosis and moderate disability received subcutaneous nonathymulin or placebo for six months, with six months of follow-up ^[7]. There was no significant difference on the Kurtzke Disability Score, Ambulation Index or Functional Scale, and no significant side effects were recorded ^[7]. The authors concluded that the compound is not effective in that population ^[7].

The other human administration record with a published abstract is a 1982 case series in three immunodeficient children given synthetic serum thymic factor intravenously ^[8]. Reported changes included reduced frequency and severity of infection and a rise in serum IgA ^[8]. That study was uncontrolled and unblinded ^[8].

No published study since 1989 reports administering thymulin to a person. The later human records that resemble thymulin trials are zinc supplementation trials or observational studies that measure thymulin as an outcome ^[9][10]. Nobody in those studies received thymulin. Two of them are a zinc supplementation trial in Gambian children and a zinc-fortified milk pilot study in very old persons ^[9][10]. In the Gambian trial, zinc had no effect on plasma thymulin in vivo ^[9]. In the fortified milk pilot study, the authors described the fortification as promising for cell-mediated immunity, represented by thymulin activity and some cytokine release ^[10]. The published abstract reports no comparative statistics for thymulin ^[10]. That abstract's favorable clinical statement is benchmarked against very old control subjects who did not take part in the crossover design ^[10]. The comparison behind it is therefore not randomized ^[10].

Two further human studies found thymic hormone activity unmoved by nutritional stress. Serum thymic factor activity was normal in moderately and severely malnourished Senegalese children ^[18]. The severely malnourished groups had very depressed protein markers, and zinc status was marginal in all the children ^[18]. Thymulin activity was unaltered across a three-week very-low-calorie diet in 13 obese women, with serum zinc in the normal range throughout ^[19]. Those authors concluded that thymulin cannot serve as a functional marker of short-term energy restriction ^[19].

No registered trial anywhere lists thymulin as an intervention ^[23]. PubMed indexes no human pharmacokinetic study of thymulin ^[24]. The only published clearance figure for administered thymulin in any species is a half-life of 10.3 minutes in one sheep, a single-animal measurement ^[14].

Preclinical research

The reason thymulin is discussed again is a 2026 mouse study reporting increased pro-inflammatory myeloid cells in aged mice and aged humans ^[11]. Integrative analysis identified thymulin, which declines with age, as a mediator suppressing pro-inflammatory cytokine production through NF-kB inhibition ^[11]. In mice, thymulin enhanced antitumor T-cell immunity, improved tumor control and survival, and sensitized tumors to anti-PD-L1 in an age-dependent way ^[11]. The human component of that study was observational cell data, not treatment ^[11]. The authors framed the finding as a potential strategy rather than a demonstrated one ^[11].

Limitations and conflicts of interest

Most of the 1978 to 1995 thymulin literature rests on an indirect rosette bioassay scored as a titer, not a mass measurement. One group found plasma thymulin activity normal in children with allergic asthma, at variance with an earlier report using the same bioassay in comparable populations ^[13]. The authors could not explain the discrepancy ^[13]. A later ELISA developed for unextracted animal serum from pigs, sheep and cattle had an interassay coefficient of variation of 24.2 percent ^[14]. Chromatography in that same animal study resolved sheep serum thymulin activity into three peaks, near 95, 80 and 1 kilodaltons ^[14]. Only the smallest of those peaks sits near the mass of the free nonapeptide ^[14].

The conflicts of interest are structural and sit inside the literature. Mireille Dardenne and Jean-Francois Bach co-authored the zinc work, the epitope work, the NMR work and the rheumatoid arthritis trials ^[1][2][3][4]. Dardenne is also a co-author on the Gambian zinc trial and on the two nutritional biomarker studies ^[9][18][19]. Dardenne was still co-authoring thymulin work in 2021, on a human study comparing thymulin activity with other markers of marginal zinc deficiency ^[20]. The single-laboratory pattern is therefore continuing rather than historical. J. Choay of Institut Choay, which manufactured the synthetic peptide, is a named co-author on the foundational zinc paper and on the 1984 arthritis communication ^[1][5]. The evidence base is substantially one laboratory's program with the manufacturer on the author line. The 2026 study is NIH-funded and declares one competing interest, an advisory role with Otsuka Pharmaceutical Factory for the senior author ^[11].

Regulatory status

No marketing authorization for thymulin is established in any jurisdiction ^[21][22]. It was never filed for approval in the United States, so it was neither refused nor withdrawn ^[22]. Japanese industrial development by Santen Pharmaceutical was discontinued rather than rejected ^[21].

FDA's National Drug Code directory does return five listings whose active ingredient is nonathymulin, four of them bulk ingredient powders from ingredient suppliers ^[17]. The fifth is Thymuline from Homeocare Laboratories, categorized as an unapproved homeopathic product, and at the dilution listed no peptide remains in it ^[17]. An NDC listing is self-submitted registration rather than an FDA review, so none of the five is an approval.

Conclusion

Thymulin's peptide chain is well characterized chemically, and three independent bench methods corroborate its zinc dependence ^[1][2][3]. Two of those three carry documented limits on zinc-selectivity. The 1982 chelation step was non-specific, and certain other metals restored some activity ^[1]. The 1985 antibody work found a zinc-independent epitope alongside the zinc-dependent one ^[2]. The identity of the sold material is a separate question. Neither of the two CAS numbers registered for the peptide encodes zinc ^[16]. No published study establishes the zinc content of a powder sold as thymulin. Its human record is one unreplicated positive publication in rheumatoid arthritis reporting two trials, one clear negative in multiple sclerosis, a small case series and two letters ^{[4][5][6][7][8]}. Development was abandoned rather than rejected, and the striking 2026 treatment findings are mouse work ^[11][21]. Specifications are on the Thymulin product page.

Frequently Asked Questions

Has thymulin been given to humans in clinical trials? Yes, but the record is small and old. Two randomized placebo-controlled trials in rheumatoid arthritis were reported in 1987, and a 1989 multiple sclerosis trial found no significant difference from placebo ^[4][7]. No published study since 1989 reports administering thymulin to a person.

Has the rheumatoid arthritis result been replicated? No. The two trials came from the same program and the same 1987 publication, and no confirmatory trial has been published since ^[4]. No registered trial anywhere lists thymulin as an intervention ^[23]. The later human records that resemble thymulin trials are zinc supplementation trials or observational studies that measure thymulin as an outcome ^[9][10].

Is thymulin the same as thymosin alpha-1, thymopentin or thymosin fraction 5? No. Thymosin alpha-1 is a 28-residue peptide, thymopentin is a pentapeptide, and thymosin fraction 5 is a thymus extract. The 2011 Cochrane review pooled those compounds and does not include thymulin ^[15].

Is thymulin FDA-approved? No, and it was never filed for approval in the United States ^[22]. FDA's drug directory carries five listings whose active ingredient is nonathymulin, four bulk ingredient powders and one unapproved homeopathic product ^[17]. Such a listing is self-submitted registration, not an approval.

References

1. 1

   Dardenne M, Pleau JM, Nabarra B, Lefrancier P, Derrien M, Choay J, Bach JF. Contribution of zinc and other metals to the biological activity of the serum thymic factor. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5370-3. PMID 6957870
2. 2

   Dardenne M, Savino W, Berrih S, Bach JF. A zinc-dependent epitope on the molecule of thymulin, a thymic hormone. Proc Natl Acad Sci U S A. 1985 Oct;82(20):7035-8. PMID 2413455
3. 3

   Cung MT, Marraud M, Lefrancier P, Dardenne M, Bach JF, Laussac JP. NMR study of a lymphocyte differentiating thymic factor. An investigation of the Zn(II)-nonapeptide complexes. J Biol Chem. 1988 Apr 25;263(12):5574-80. PMID 3356698
4. 4

   Amor B, Dougados M, Mery C, Dardenne M, Bach JF. Nonathymulin in rheumatoid arthritis: two double blind, placebo controlled trials. Ann Rheum Dis. 1987 Jul;46(7):549-54. PMID 3310925
5. 5

   Amor B, Dougados M, Mery C, de Gery A, Choay J, Dardenne M, Bach JF. Thymuline (FTS) in rheumatoid arthritis. Arthritis Rheum. 1984 Jan;27(1):117-8. PMID 6362675
6. 6

   Faure GC, Bene MC, Thomas P, Tamisier JN. An open trial of thymulin (FTS-Zn) in rheumatoid arthritis patients: sequential clinical and immunological follow-up. Clin Exp Rheumatol. 1987 Jul-Sep;5(3):291-3. PMID 3427844
7. 7

   Roullet E, Cesaro P, Simon-Lavoine N, Degos JD, Marteau R. Nonathymulin treatment of multiple sclerosis: double-blind pilot study. Acta Neurol Scand. 1989 Dec;80(6):575-8. PMID 2618585
8. 8

   Bordigoni P, Faure G, Bene MC, Dardenne M, Bach JF, Duheille J, Olive D. Improvement of cellular immunity and IgA production in immunodeficient children after treatment with synthetic serum thymic factor. Lancet. 1982 Aug 7;2(8293):293-7. PMID 6124716
9. 9

   Bates CJ, Evans PH, Dardenne M, et al. A trial of zinc supplementation in young rural Gambian children. Br J Nutr. 1993 Jan;69(1):243-55. PMID 8457531
10. 10

    Costarelli L, Giacconi R, Malavolta M, et al. Effects of zinc-fortified drinking skim milk (as functional food) on cytokine release and thymic hormone activity in very old persons: a pilot study. Age (Dordr). 2014 Jun;36(3):9656. PMID 24771015
11. 11

    Kanemaru H, Luong S, Yamamoto Y, Mizukami Y, Ito F. Thymulin restrains age-associated myeloid inflammation and enhances cancer immunotherapy. Nat Commun. 2026 Jul 21;17(1):6534. PMID 42481458
12. 12

    Haddad JJ. Endotoxin-mediated regulation of nuclear factor-kappaB nuclear translocation and activation in the hippocampus. Neuroscience. 2009 Dec 29;164(4):1509-20. PMID 19782726. RETRACTED, retraction notice Neuroscience. 2010 Aug 11;169(1):558
13. 13

    Lurie A, Chaussain M, Raynaud F, et al. Serum thymic hormone thymulin activity is normal in children with asthma. J Allergy Clin Immunol. 1989 Sep;84(3):386-90. PMID 2674264
14. 14

    Davis SL, Safieh-Garabedian B, Khosraviani M. Concentrations of thymulin in unextracted serum from pigs, sheep and cattle as measured by ELISA. J Immunoassay. 1994 May;15(2):191-211. PMID 8040352
15. 15

    Wolf E, Milazzo S, Boehm K, Zwahlen M, Horneber M. Thymic peptides for treatment of cancer patients. Cochrane Database Syst Rev. 2011 Feb 16;2011(2):CD003993. PMID 21328265
16. 16

    PubChem CID 3085284 (title Nonathymulin, CAS 63958-90-7) and CID 71300623 (CAS 78922-62-0). NCBI PubChem, retrieved 2026-08-28
17. 17

    openFDA National Drug Code directory, query active_ingredients.name:"NONATHYMULIN", five results, retrieved 2026-08-28
18. 18

    Maire B, Wade S, Bleiberg F, Dardenne M, Parent G, Le Francois P, Carles C. Absence of variation in facteur thymique serique activity in moderately and severely malnourished Senegalese children. Am J Clin Nutr. 1982 Dec;36(6):1129-33. PMID 6816060
19. 19

    Bleiberg-Daniel F, Fricker J, Dardenne M, Chappuis P, Apfelbaum M. Thymulin activity during very-low-calorie diet. Eur J Clin Nutr. 1992 Apr;46(4):297-9. PMID 1600927
20. 20

    DiSilvestro RA, Dardenne M, Joseph E. Comparison of thymulin activity with other measures of marginal zinc deficiency. Biol Trace Elem Res. 2021 Feb;199(2):585-587. PMID 32363520
21. 21

    NCATS Inxight Drugs record for nonathymulin, FDA UNII 9H198D04WL: development status investigational, Japanese development by Santen Pharmaceutical discontinued. Retrieved 2026-08-28
22. 22

    openFDA Drugs@FDA endpoint, no records returned for thymulin or nonathymulin on openfda.substance_name, openfda.generic_name, products.active_ingredients.name or products.brand_name, retrieved 2026-08-28
23. 23

    ClinicalTrials.gov API v2, query.intr=thymulin, zero studies; EU Clinical Trials Register, thymulin returns only the zinc trial EudraCT 2014-004499-47, retrieved 2026-08-28
24. 24

    PubMed search, thymulin AND (pharmacokinetic* OR half-life OR bioavailability), 16 records, none a human pharmacokinetic study, retrieved 2026-08-28